Resminostat, recently met the primary endpoint in a Phase II study in advanced liver cancer. The therapy mediates tumour cell "resensitisation" with a novel epigenetic mode of action. Resensitisation can suppress or reverse drug tolerance mechanisms that tumour cells can develop against cancer drugs. The supplementary administration of resminostat can enable the effective treatment of patients with cancer drugs to which patient response is no longer adequate.
Broadcast live, record and publish your investor, corporate and analyst videos on 3B NEXUS for our targeted distribution. 3bnexus.com